VIDEO: EyePoint presents update on phase 2 trial of EYP-1901 for wet AMD
Click Here to Manage Email Alerts
SEATTLE — In this Healio Video Perspective from OIS Retina, Nancy Lurker discusses an update on the ongoing phase 2 DAVIO 2 trial, as well as the demographic data in the completed phase 1 DAVIO 1 trial and the DAVIO 2 trial.
DAVIO 2 is investigating EYP-1901 for the treatment of wet age-related macular degeneration.
“The results were quite good between the patient demographics,” Lurker said. “We feel we have a more typical patient demographic in DAVIO 2. And particularly given the safety results that we are seeing so far on a masked basis, with no serious adverse events that are drug related, we are pleased with where we are right now with DAVIO 2.”
A topline data readout for DAVIO 2 is expected in December, she said.
Collapse
Lurker N. Spotlight on drug delivery. Presented at: OIS Retina; July 27, 2023; Seattle.
Read more about
Click Here to Manage Email Alerts